

**Table S2. Strains and Plasmids**

Strain or plasmid	Relevant characteristics <sup>a</sup>	Source and/or reference
<b>Strains</b>		
<b><i>Burkholderia cenocepacia</i></b>		
K56-2	ET12 clone related to J2315, CF clinical Isolate	<sup>b</sup> BCRRC, (1)
OME19	K56-2 pSCRhaB2; Tp <sup>R</sup>	(2)
OME37	K56-2 pOE12; BCAL3310 with C-terminus FLAG tag; Tet <sup>R</sup>	This study
OME40	K56-2 pOE13; BCAL3311 with C-terminus FLAG tag; Tet <sup>R</sup>	This study
OME60	K56-2, <i>P<sub>BCAL3310</sub>::pGSVTp-luxCDABE</i> ; Tp <sup>R</sup>	This study
OME61	K56-2, <i>P<sub>BCAL3312-3311</sub>::pGSVTp-luxCDABE</i> ; Tp <sup>R</sup>	This study
OME62	K56-2, $\Delta$ BCAL3311	This study
OME65	K56-2, $\Delta$ BCAL3310	This study
OME66	K56-2 pDA17; Tet <sup>R</sup>	This study
OME71	OME62 pSCRhaB2; Tp <sup>R</sup>	This study
OME72	OME62 pOE33 (BCAL3311); Tp <sup>R</sup>	This study
OME73	OME62 pOE34 (PA0423); Tp <sup>R</sup>	This study
OME74	OME62 pOE35 (PA4340); Tp <sup>R</sup>	This study
OME75	OME62 pOE36 (PA4345); Tp <sup>R</sup>	This study
OME76	OME62 pOE37 (Rv1890c); Tp <sup>R</sup>	This study
OME77	OME62 pOE38 (SAUSA300_2620); Tp <sup>R</sup>	This study
<b><i>Escherichia coli</i></b>		
DH5 $\alpha$	F $^-\phi 80lacZ M15 endA1 recA1 supE44 hsdR17(r_K^- m_K^+)deoR thi-1 nupG supE44 gyrA96relA1 \Delta(lacZYA-argF)U169, \lambda-$	Laboratory stock
GT115	F $^-mcrA\Delta(mrr-hsdRMS-mcrBC) \phi 80\Delta lacZ\Delta M15 \Delta lacX74 recA1 rpsL$ (Stra) <i>endA1</i> $\Delta dcm uidA(\Delta MluI)::pir-116 \Delta sbcC-sbcD$	Invivogen, San Diego, CA
BL21	F $^-dcm ompT hsdS(r_B^- m_B^-) gal$	Novagen
<b><i>Pseudomonas aeruginosa</i></b>		
PAO1	Non-CF clinical isolate	(3)
Q502	CF clinical isolate	(4)
<b><i>Salmonella typhi</i></b>		
SARB63		(5)
<b><i>Shigella flexneri</i></b>		
SF51571	Serotype 1a, antigenic formula 1:4	Laboratory stock
<b><i>Acinetobacter</i> species</b>		
<i>A. baumannii</i> (AB1)	Clinical isolate	LHSC <sup>c</sup>
<i>A. lwoffii</i> (AB2)	Clinical isolate	LHSC <sup>c</sup>
<i>A. junii</i> (AB3)	Clinical isolate	LHSC <sup>c</sup>

<b>Klebsiella pneumoniae</b>		
Kpn18	Clinical isolate	Laboratory stock
<b>Staphylococcus aureus</b>		
USA300	Community acquired MRSA	Martin McGavin
<b>Plasmids</b>		
pRK2013	<i>ori<sub>colE1</sub></i> , RK2 derivative, Kan <sup>R</sup> , <i>mob</i> <sup>+</sup> , <i>tra</i> <sup>+</sup>	(6)
pGSVTp-lux	Mobilizable suicide vector containing lux operon, derivative from pGSV3-lux(7); OriT; Tp <sup>R</sup>	(8)
pSCRhaB2	<i>ori<sub>pBBR1</sub>rhaR</i> , <i>rhaS</i> , <i>P<sub>rhaB</sub>Tp</i> <sup>R</sup> <i>mob</i> <sup>+</sup>	(9)
pDAI-SceI-SacB	<i>ori<sub>pBBR1</sub></i> , Tet <sup>R</sup> , <i>P<sub>dfr</sub></i> , <i>mob</i> <sup>+</sup> , expressing I-SceI, SacB	(10)
pGPI-SceI	<i>ori<sub>R6K</sub></i> , ΩTp <sup>R</sup> , <i>mob</i> <sup>+</sup> , including an I-SceI restriction site	(11)
pDA17	<i>ori<sub>pBBR1</sub></i> , Tet <sup>R</sup> , <i>mob</i> <sup>+</sup> , <i>P<sub>dfr</sub></i> , FLAG epitope	D. Aubert, unpublished
pOE12	pDA17, BCAL3310, C-terminus FLAG, Tet <sup>R</sup>	This study
pOE13	pDA17, BCAL3311, C-terminus FLAG, Tet <sup>R</sup>	This study
pOE15	BCAL3310 without signal peptide encoding sequence cloned in pET28a(+)	(2)
pOE16	BCAL3311 without signal peptide encoding sequence cloned in pET28a(+)	(2)
pOE22	<i>P<sub>BCAL3310</sub>::luxCDABE</i> transcriptional fusion in pGSVTp-lux, Tp <sup>R</sup>	This study
pOE23	<i>P<sub>BCAL3312-3311</sub>::luxCDABE</i> transcriptional fusion in pGSVTp-lux, Tp <sup>R</sup>	This study
pOE25	pGPI-SceI with fragments flanking BCAL3310, Tp <sup>R</sup>	This study
pOE26	pGPI-SceI with fragments flanking BCAL3311, Tp <sup>R</sup>	This study
pOE33	pSCRhaB2, BCAL3311, Tp <sup>R</sup>	This study
pOE34	pSCRhaB2, PA0423, Tp <sup>R</sup>	This study
pOE35	pSCRhaB2, PA4340, Tp <sup>R</sup>	This study
pOE36	pSCRhaB2, PA4345, Tp <sup>R</sup>	This study
pOE37	pSCRhaB2, Rv1890c, Tp <sup>R</sup>	This study
pOE38	pSCRhaB2, SAUSA300_2620, Tp <sup>R</sup>	This study
pOE39	pOE16, D82A	This study
pOE41	pOE16, D93A	This study
pOE46	pOE39, D93A	This study

<sup>a</sup>Tp<sup>R</sup>, trimethoprim resistance, Kan<sup>R</sup>, kanamycin resistance, Tet<sup>R</sup>, tetracycline resistance.

<sup>b</sup>BCRRC, *B. cepacia* Research and Referral Repository for Canadian CF Clinics.

<sup>c</sup>LHSC, London Health Science Centre, London, Ontario, Canada.

## TABLE REFERENCES

1. Mahenthiralingam E, Coenye T, Chung JW, Speert DP, Govan JR, Taylor P, Vandamme P. 2000. Diagnostically and experimentally useful panel of strains from the *Burkholderia cepacia* complex. J. Clin. Microbiol. 38:910-913.

2. **El-Halfawy OM, Valvano MA.** 2013. Chemical communication of antibiotic resistance by a highly resistant subpopulation of bacterial cells. *PLoS One* **8**:e68874.
3. **Holloway BW.** 1955. Genetic recombination in *Pseudomonas aeruginosa*. *J Gen Microbiol* **13**:572-581.
4. **Camper N, Glasgow AM, Osbourn M, Quinn DJ, Small DM, McLean DT, Lundy FT, Elborn JS, McNally P, Ingram RJ, Weldon S, Taggart CC.** 2016. A secretory leukocyte protease inhibitor variant with improved activity against lung infection. *Mucosal Immunol* **9**:669-676.
5. **Boyd EF, Wang FS, Beltran P, Plock SA, Nelson K, Selander RK.** 1993. *Salmonella* reference collection B (SARB): strains of 37 serovars of subspecies I. *J Gen Microbiol* **139 Pt 6**:1125-1132.
6. **Figurski DH, Helinski DR.** 1979. Replication of an origin-containing derivative of plasmid RK2 dependent on a plasmid function provided in *trans*. *Proc Natl Acad Sci USA* **76**:1648-1652.
7. **Moore RA, Reckseidler-Zenteno S, Kim H, Nierman W, Yu Y, Tuanyok A, Warawa J, DeShazer D, Woods DE.** 2004. Contribution of gene loss to the pathogenic evolution of *Burkholderia pseudomallei* and *Burkholderia mallei*. *Infect Immun* **72**:4172-4187.
8. **Bernier SP, Nguyen DT, Sokol PA.** 2008. A LysR-type transcriptional regulator in *Burkholderia cenocepacia* influences colony morphology and virulence. *Infect Immun* **76**:38-47.
9. **Cardona ST, Valvano MA.** 2005. An expression vector containing a rhamnose-inducible promoter provides tightly regulated gene expression in *Burkholderia cenocepacia*. *Plasmid* **54**:219-228.
10. **Hamad MA, Skeldon AM, Valvano MA.** 2010. Construction of aminoglycoside-sensitive *Burkholderia cenocepacia* strains for use in studies of intracellular bacteria with the gentamicin protection assay. *Appl Environ Microbiol* **76**:3170-3176.
11. **Flannagan RS, Linn T, Valvano MA.** 2008. A system for the construction of targeted unmarked gene deletions in the genus *Burkholderia*. *Environ. Microbiol.* **10**:1652-1660.